GlassScriptPhysician profile
Kathy A Nieder
NPI 1639158207
$415.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $130 · 2021: $44.21 · 2022: $50.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $76.74 | 2019-2020 | |
| Astellas Pharma US INC | $56.99 | 2019 | |
| Glaxosmithkline, LLC. | $52.92 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $44.21 | 2021 | |
| Pfizer INC. | $41.89 | 2019-2020 | |
| Novo Nordisk INC | $37.87 | 2019-2022 | |
| Allergan, INC. | $27.54 | 2019-2020 | |
| Sanofi Pasteur INC. | $22.49 | 2019 | |
| Gilead Sciences, INC. | $18.21 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.40 | 2019 | |
| Incyte Corporation | $12.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Nieder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.